New drug TST003 tested in patients with advanced cancers
NCT ID NCT05731271
First seen Jan 05, 2026 · Last updated May 16, 2026 · Updated 20 times
Summary
This early-stage study tests a new drug called TST003 in about 111 adults with advanced solid tumors (cancers that have spread or cannot be removed by surgery). The main goals are to find a safe dose, check side effects, and see if the drug can shrink tumors. Participants receive TST003 through a vein every three weeks and are monitored closely with blood tests and scans.
Disclaimer
Read more
Show less
This is a summary of
the original study
.
Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for COLORECTAL ADENOCARCINOMA are added.
By submitting, you agree to our Terms of use
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
Mary Crowley
Dallas, Texas, 75231, United States
-
NEXT Oncology
San Antonio, Texas, 78229, United States
-
OHSU
Portland, Oregon, 97239, United States
Conditions
Explore the condition pages connected to this study.